WHO ICTRP trial
Melatonin on the outcome of patients with Polycystic ovarian syndrome
IRCT20250126064525N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20250126064525N1 |
|---|---|
| Public title | Melatonin on the outcome of patients with Polycystic ovarian syndrome |
| Scientific title | Studying the effect of melatonin on the outcome of patients with Polycystic ovarian syndrome treated with intrauterine insemination |
| Primary sponsor | Esfahan University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Polycystic Ovarian syndrome. Polycystic ovarian syndrome;E28.2 |
| Interventions | Intervention 1: Intervention group: Administered 1 oral melatonin tablet, 5 mg, manufactured by Razak Company, once a day. Intervention 2: Control group: Administered 1 placebo tablet manufactured by Isfahan Faculty of Pharmacy once a day. |
| Registration date | Jan 29, 2025 |
| Target size | 200 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: